19M Am i a minoxidil hyper responder?
    Progress Pictures 6/19/2024

    From the encyclopedia
    Minoxidil β†’

    An essential vasodilator with some anti-androgenic effects

    Dutasteride β†’

    Heavy duty finasteride that comes with higher risks

    Finasteride β†’

    Frontline, gold standard treatment for combatting androgenic alopecia

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    πŸ’§ Minoxidil (topical) 1.5ml to 2ml 1x daily 3 months
    πŸ’Š Dutasteride (oral) 0.5mg daily 52 days
    πŸ’Š Finasteride (oral) 3 months
    πŸ’Š Accutane (oral) 20mg 3x weekly
    the tone is πŸ˜€ positive with significant hair growth results.

    Other terms

    A 19-year-old using topical minoxidil and dutasteride reports significant hair growth and shedding. Minoxidil caused new facial hair growth, and the user hopes for thicker hair regrowth.
    View this post in the Community β†’

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results
      Finasteride in Androgenetic Alopecia in Men

      research Finasteride in androgenetic alopecia in men

      June 2007 in “Advances in Dermatology and Allergology/PostΔ™py Dermatologii i Alergologii”
      This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.
      The Inflammatory Component of Androgenetic Alopecia

      research The inflammatory component of androgenetic alopecia

      3 citations , November 2021 in “Journal of The American Academy of Dermatology”
      This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.
      Updates in Treatment for Androgenetic Alopecia

      research Updates in Treatment for Androgenetic Alopecia

      January 2025 in “Annals of Dermatology”
      This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.